BACKGROUND: The study was conducted to determine whether radiofrequency ablation (RFA) can safely reduce pain from osseous metastatic disease. METHODS: The single-arm prospective trial included patients with a single painful bone metastasis with unremitting pain with a score >50 on a pain scale of 0-100. Percutaneous computed tomography-guided RFA of the bone metastasis to temperatures >60 degrees C was performed. Endpoints were the toxicity and pain effects of RFA before and at 2 weeks, 1 month, and 3 months after RFA. RESULTS: Fifty-five patients completed RFA. Grade 3 toxicities occurred in 3 of 55 (5%) patients. RFA reduced pain at 1 and 3 months for all pain assessment measures. The average increase in pain relief from pre-RFA to 1-month follow-up is 26.3 (95% confidence interval [CI], 17.7-34.9; P < .0001), and the increase from pre-RFA to 3-month follow-up is 16.38 (95% CI, 3.4-29.4; P = .02). The average decrease in pain intensity from pre-RFA to 1-month follow-up was 26.9 (P < .0001) and 14.2 for 3-month follow-up (P = .02). The odds of lower pain severity at 1-month follow-up were 14.0 (95% CI, 2.3-25.7; P < .0001) times higher than at pre-RFA, and the odds at 3-month follow-up were 8.0 (95% CI, 0.9-15.2; P < .001) times higher than at pre-RFA. The average increase in mood from pre-RFA to 1-month follow-up was 19.9 (P < .0001) and 14.9 to 3-month follow-up (P = .005). CONCLUSIONS: This cooperative group trial strongly suggests that RFA can safely palliate pain from bone metastases.
BACKGROUND: The study was conducted to determine whether radiofrequency ablation (RFA) can safely reduce pain from osseous metastatic disease. METHODS: The single-arm prospective trial included patients with a single painful bone metastasis with unremitting pain with a score >50 on a pain scale of 0-100. Percutaneous computed tomography-guided RFA of the bone metastasis to temperatures >60 degrees C was performed. Endpoints were the toxicity and pain effects of RFA before and at 2 weeks, 1 month, and 3 months after RFA. RESULTS: Fifty-five patients completed RFA. Grade 3 toxicities occurred in 3 of 55 (5%) patients. RFA reduced pain at 1 and 3 months for all pain assessment measures. The average increase in pain relief from pre-RFA to 1-month follow-up is 26.3 (95% confidence interval [CI], 17.7-34.9; P < .0001), and the increase from pre-RFA to 3-month follow-up is 16.38 (95% CI, 3.4-29.4; P = .02). The average decrease in pain intensity from pre-RFA to 1-month follow-up was 26.9 (P < .0001) and 14.2 for 3-month follow-up (P = .02). The odds of lower pain severity at 1-month follow-up were 14.0 (95% CI, 2.3-25.7; P < .0001) times higher than at pre-RFA, and the odds at 3-month follow-up were 8.0 (95% CI, 0.9-15.2; P < .001) times higher than at pre-RFA. The average increase in mood from pre-RFA to 1-month follow-up was 19.9 (P < .0001) and 14.9 to 3-month follow-up (P = .005). CONCLUSIONS: This cooperative group trial strongly suggests that RFA can safely palliate pain from bone metastases.
Authors: Jean S Kutner; Marlaine C Smith; Lisa Corbin; Linnea Hemphill; Kathryn Benton; B Karen Mellis; Brenda Beaty; Sue Felton; Traci E Yamashita; Lucinda L Bryant; Diane L Fairclough Journal: Ann Intern Med Date: 2008-09-16 Impact factor: 25.391
Authors: Matthew P Goetz; Matthew R Callstrom; J William Charboneau; Michael A Farrell; Timothy P Maus; Timothy J Welch; Gilbert Y Wong; Jeff A Sloan; Paul J Novotny; Ivy A Petersen; Robert A Beres; Daniele Regge; Rodolfo Capanna; Mark B Saker; Dietrich H W Grönemeyer; Athour Gevargez; Kamran Ahrar; Michael A Choti; Thierry J de Baere; Joseph Rubin Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Matthew R Callstrom; J William Charboneau; Matthew P Goetz; Joseph Rubin; Gilbert Y Wong; Jeff A Sloan; Paul J Novotny; Bradley D Lewis; Timothy J Welch; Michael A Farrell; Timothy P Maus; Robert A Lee; Carl C Reading; Ivy A Petersen; Deitra D Pickett Journal: Radiology Date: 2002-07 Impact factor: 11.105
Authors: Dimitrios K Filippiadis; Steven Yevich; Frederic Deschamps; Jack W Jennings; Sean Tutton; Alexis Kelekis Journal: Curr Oncol Rep Date: 2019-11-25 Impact factor: 5.075
Authors: Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini Journal: Eur Thyroid J Date: 2021-05-25
Authors: Matthew R Callstrom; Damian E Dupuy; Stephen B Solomon; Robert A Beres; Peter J Littrup; Kirkland W Davis; Ricardo Paz-Fumagalli; Cheryl Hoffman; Thomas D Atwell; J William Charboneau; Grant D Schmit; Matthew P Goetz; Joseph Rubin; Kathy J Brown; Paul J Novotny; Jeff A Sloan Journal: Cancer Date: 2012-10-12 Impact factor: 6.860